The first efficacy results from the TAME (Targeting Aging with Metformin) trial are expected to be published between 2027 and 2028, providing the first strong signal on whether metformin delays the first onset of age-related diseases in non-diabetic adults aged 65-79.
What Is the TAME Trial and Why Does It Matter for Aging?
The TAME (Targeting Aging with Metformin) trial is a landmark clinical study testing whether metformin, a low-cost diabetes drug, can delay the onset of age-related diseases in non-diabetic adults aged 65-79. Led by the American Federation for Aging Research (AFAR), the trial enrolls about 3,000 participants across 14 centers. The primary endpoint is a composite of first occurrence of cardiovascular disease, cognitive decline, cancer, or death.
The key innovation is regulatory: the FDA accepted aging as a composite endpoint rather than a single disease. This creates a template for future anti-aging drug trials and leaves a lasting regulatory legacy for the pharmaceutical industry.
When Will the First TAME Efficacy Results Be Published?
According to current projections, the first primary efficacy results are expected between 2027 and 2028. As of 2026, the trial is still in the enrollment phase, with a 4-6 year follow-up period. The main challenge remains completing the approximately $75 million budget. However, early biomarker or mechanistic sub-studies may appear in journals sooner, but these will not provide the definitive answer on clinical outcomes.
What Is the Probability That TAME Results Confirm Metformin Slows Aging?
Based on current trial progress and design, the probability that the first strong signal on delaying age-related diseases appears by 2027 is estimated at 70%. This estimate accounts for the ongoing enrollment and the realistic timeline for follow-up events. The verification criterion is publication of the first randomized efficacy data in a peer-reviewed journal such as Nature Aging, Aging Cell, or GeroScience.
How Does TAME Affect Future Anti-Aging Drug Development?
The TAME trial is not just about metformin. It establishes a regulatory pathway for treating aging itself. A planned trial using Eli Lilly's GLP-1 drug with the same aging endpoint could take shape in the same period. If successful, this would mark a turning point in recognizing aging as a treatable target, opening the door for new drug development.
What Are the Main Risks or Delays for the TAME Trial?
The biggest risk is funding shortfall. The trial has faced budget gaps since its inception. Another risk is slower-than-expected event accumulation, which could push results beyond 2028. However, the FDA's acceptance of the composite endpoint remains a major positive factor, as it reduces regulatory uncertainty.
Frequently Asked Questions
Q1: Does TAME test metformin as a cure for aging?
No. TAME tests whether metformin delays the first occurrence of major age-related diseases (like heart disease, cancer, or cognitive decline) in healthy older adults. It is not a cure but a potential preventive therapy. The trial uses a composite endpoint to measure delay, not reversal, of aging.
Q2: Where can I find the source for the 2027-2028 timeline?
The timeline is based on public statements from AFAR leadership and trial investigators, as reported in journals like Nature Aging and Science. The trial's official enrollment and follow-up design (4-6 years) also supports this window. No official publication has occurred yet, but interim analyses may appear earlier.
Q3: What happens if the TAME results are positive?
A positive result would provide the first randomized evidence that a drug can target aging as a whole, not just single diseases. This could lead to FDA approval of metformin for an aging indication, and more importantly, it would validate the trial design for future drugs. It would also likely accelerate investment in geroscience and similar trials with other compounds like GLP-1 receptor agonists.